B
BioCardia, Inc.
BCDACIK 0000925741NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-8.23M
Total Assets
$3.41M
Equity
$895.0K
Shares Out
10.94M
Op. Cash Flow
$-7.44M
Business
BioCardia, Inc. is a publicly listed company in Biological Products, (No Diagnostic Substances), incorporated in Delaware. Common stock trades on Nasdaq under the ticker BCDA.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration agreement revenue | 0 | 58,000 | 477,000 | 1 | 1 | |
| Research and development | 5 | 4 | 8 | 9 | 9 | |
| Selling, general and administrative | 3 | 4 | 4 | 4 | 5 | |
| Total costs and expenses | 8 | 8 | 12 | 13 | 14 | |
| Operating loss | −8 | −8 | −12 | −12 | −13 | |
| Total other income, net | 50,000 | 55,000 | 73,000 | −6,000 | 7,000 | |
| Net loss | −8 | −8 | −12 | −12 | −13 | |
| Net loss per share, basic and diluted (in dollars per share) | −1.23 | −2.9 | −8.19 | −0.67 | −0.75 | |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 7 | 3 | 1 | 18 | 17 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 2 | 1 | 7 | 13 | |
| Accounts receivable, net of allowance for doubtful accounts of $0 and $0 as of December 31, 2025 and 2024, respectively | 20,000 | 0 | 63,000 | 201,000 | 147,000 | |
| Prepaid expenses | 216,000 | 251,000 | 295,000 | 300,000 | 462,000 | |
| Total current assets | 3 | 3 | 1 | 8 | 13 | |
| Property and equipment, net | 16,000 | 33,000 | 94,000 | 170,000 | 182,000 | |
| Operating lease right-of-use asset, net | 494,000 | 898,000 | 1 | 2 | 2 | |
| Other assets | 171,000 | 171,000 | 171,000 | 171,000 | 172,000 | |
| Total assets | 3 | 4 | 3 | 10 | 16 | |
| Accounts payable | 641,000 | 385,000 | 890,000 | 683,000 | 507,000 | |
| Accrued expenses and other current liabilities | 1 | 2 | 2 | 2 | 2 | |
| Operating lease liability - current | 442,000 | 385,000 | 333,000 | 315,000 | 237,000 | |
| Total current liabilities | 2 | 2 | 4 | 4 | 4 | |
| Operating lease liability - noncurrent | 86,000 | 566,000 | 982,000 | 1 | 2 | |
| Total liabilities | 3 | 3 | 5 | 5 | 5 | |
| Commitments and Contingencies | — | — | — | — | — | |
| Preferred stock, $0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value, 50,000,000 shares authorized, 10,755,647 and 4,600,910 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 11,000 | 5,000 | 2,000 | 20,000 | 17,000 | |
| Additional paid-in capital | 169 | 161 | 151 | 145 | 139 | |
| Accumulated deficit | −168 | −160 | −152 | −141 | −129 | |
| Total stockholders equity | 895,000 | 837,000 | −2 | 5 | 10 | |
| Total liabilities and stockholders equity | 3 | 4 | 3 | 10 | 16 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 24,000 | 67,000 | 84,000 | 82,000 | 60,000 | |
| Reduction in the carrying amount of right-of-use assets | 481,000 | 482,000 | 327,000 | 295,000 | 580,000 | |
| Share-based compensation | 430,000 | 741,000 | 1 | 1 | 2 | |
| Allowance for doubtful accounts | 0 | −34,000 | 23,000 | — | — | |
| Accounts receivable | 20,000 | −97,000 | −115,000 | 54,000 | 85,000 | |
| Prepaid expenses | 35,000 | 44,000 | −5,000 | −163,000 | −179,000 | |
| Accounts payable | 163,000 | −316,000 | 184,000 | 4,000 | −239,000 | |
| Accrued expenses and other current liabilities | 179,000 | −538,000 | 482,000 | 416,000 | 130,000 | |
| Operating lease liability | −500,000 | −483,000 | −316,000 | — | — | |
| Net cash used in operating activities | −7 | −8 | −10 | −11 | −10 | |
| Purchase of property and equipment | −7,000 | −6,000 | −12,000 | −70,000 | −116,000 | |
| Net cash used in investing activities | −7,000 | −6,000 | −12,000 | −70,000 | −116,000 | |
| Exercise of common stock warrants | 5,000 | 0 | — | — | — | |
| Taxes paid related to net share settlement of equity awards | −197,000 | −140,000 | — | — | 0 | |
| Proceeds from sales of common stock | 9 | 11 | 4 | 6 | 2 | |
| Issuance costs of sale of common stock | −930,000 | −1 | 662,000 | 418,000 | −59,000 | |
| Net cash provided by financing activities | 8 | 9 | 4 | 5 | 2 | |
| Net change in cash and cash equivalents | 125,000 | 1 | −6 | −6 | −9 | |
| Unpaid issuance costs of common stock | 99,000 | 6,000 | 195,000 | 172,000 | 0 | |
| Restricted stock units issued to settle management bonus obligations | 184,000 | 156,000 | 564,000 | 401,000 | 393,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro